Targeting CCL2/CCR2 signaling overcomes MEK inhibitor resistance in Acute Myeloid Leukemia

CONCLUSIONS: Our study demonstrates a compelling rationale for translating CCL2/CCR2 axis inhibitors in combination with MEK pathway-targeting therapies, as a potent strategy for combating drug resistance in AML. This approach has the potential to enhance the efficacy of treatments to improve AML patient outcomes.PMID:38451486 | DOI:10.1158/1078-0432.CCR-23-2654

Source: Clinical Cancer Research - March 7, 2024 Category: Cancer & Oncology Authors: Rucha V Modak Katia G de Oliveira Rebola John McClatchy Mona Mohammadhosseini Alisa Damnernsawad Stephen E Kurtz Christopher A Eide Guanming Wu Ted Laderas Tamilla Nechiporuk Marina A Gritsenko Joshua R Hansen Chelsea Hutchinson Sara J C Gosline Paul Pieh Source Type: research